Julia Martinez-Sanchez

Dr. Julia Martinez-Sanchez

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2023 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
JMJulia Martinez-Sanchez
Julia Martinez-Sanchez
MPMarta Palomo
Marta Palomo
APAlexandra Pedraza
Alexandra Pedraza
AMAna Belén Moreno‐Castaño
Ana Belén Moreno‐Castaño
STSergi Torramade‐Moix
Sergi Torramade‐Moix
MDMaribel Diaz-Ricart
Maribel Diaz-Ricart
Graft-versus-host disease (GVHD) is a complication of allogeneic haematopoietic cell transplantation. Endothelial injury is crucial as pathophysiological substrate for GVHD. GVHD first-line treatment is high-dose corticosteroids, although some patients are steroid-refractory. Through the present study, we compared the endothelial proteomic profiles in response to serum from steroid-refractory acute GVHD (SR-aGVHD) and steroid-sensitive acute GVHD (SS-aGVHD) patients. Blood samples from SR-aGVHD (n = 4) and SS-aGVHD (n = 8) patients were collected at aGVHD diagnosis. Endothelial cell cultures were exposed (48 h) to patients' serum. Protein extraction and proteomic analysis were performed. Differences were statistically evaluated by multivariate analysis. Forty-four proteins contributed to separate all samples into the two study groups, among which 15 participated significantly (p < 0.05), 10 exhibiting a fold change >1.2. Differentially expressed proteins were mainly associated with oxidative phosphorylation (Cytochrome C oxidase subunit 6B1, CX6B1), inflammation and angiogenesis (Apolipoprotein D, APOD), cell survival (Rapamycin-insensitive companion of mTOR, RICTR), and oxidative stress (Riboflavin kinase, RIFK). This pilot study used a novel approach to distinguish the aGVHD response to steroid treatment. The proteins differentially expressed could constitute potential biomarkers for steroid-treatment response. These findings signify a step forward to identify the mechanisms of response to steroids, of high clinical relevance considering the SR-aGVHD elevated mortality.

21 October 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Closed access
FPFilipe R. Pinto
Filipe R. Pinto
MSMaría Queralt Salas
María Queralt Salas
MSMaría Suárez-Lledó
María Suárez-Lledó
APAlexandra Pedraza
Alexandra Pedraza
PCPaola Andrea Charry
Paola Andrea Charry
HBHOSPITAL CLINIC OF BARCELONA
HOSPITAL CLINIC OF BARCELONA

27 March 2026 in Blood Advances
Verified
Journal Article
Open access
RGRaquel Sarahí Salinas Gonzalez
Raquel Sarahí Salinas Gonzalez
LRLAIA GUARDIA ROCA
LAIA GUARDIA ROCA
BSBerta Solé
Berta Solé
CMCristina Moreno
Cristina Moreno
NLNoemi de Llobet
Noemi de Llobet
MSMaria Queralt Salas
Maria Queralt Salas
Frailty has emerged as a key component of allo-HCT candidate assessment and is closely associated with transplant outcomes. Exercise-based prehabilitation may improve transplant candidacy, yet real-world implementation is limited. Our institution implemented a structured Frailty Program (FP) to assess frailty and introduce prehabilitation interventions. This study describes the program’s evolution and evaluates the impact of prehabilitation. Between April 2021 and April 2025, 185 consecutive allo-HCT candidates were included in 3 sequential FP phases. In the first phase (No-Prehab, n = 76), patients underwent frailty assessment only. In the second phase (Pilot-Prehab, n = 59), patients received a home-based, nonsupervised prehabilitation program. In the third phase (Tele-Prehab, n = 50), patients participated in the HCT Pre-App Program, a structured digital telemedicine intervention supervised by rehabilitation physicians. Frailty was assessed at first consultation and HCT admission using the HCT Frailty Scale. Median prehabilitation duration was 6 weeks. Adherence was high across frailty groups (76%-88%), with no adverse events. Prehabilitation improved frailty status: fit patients increased from 22% to 42% in the Pilot-Prehab cohort (P = .009) and from 34% to 56% in the Tele-Prehab cohort (P = .001). Tele-Prehab independently increased the odds of being fit at admission (odds ratio [OR], 3.86; P = .001) and reduced frailty incidence (OR, 0.17; P = .031). One-year OS and NRM were comparable across cohorts (OS, 74.5%, 84.5%, and 78.1%; P = .367) with a trend toward lower NRM among prehabilitated patients (NRM, 14.6%, 5.1%, and 5.6%; P = .075). Frailty is dynamic in allo-HCT candidates, and results support how home-based digital prehabilitation improves fitness before transplantation.

15 June 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JMJulia Martinez-Sanchez
Julia Martinez-Sanchez
PCPaola Charry
Paola Charry
AMAna Belén Moreno-Castaño
Ana Belén Moreno-Castaño
ARAlex Ramos
Alex Ramos
STSergi Torramade-Moix
Sergi Torramade-Moix
MDMaribel Diaz-Ricart
Maribel Diaz-Ricart
Introduction: Extracorporeal photopheresis (ECP) is a safe, effective treatment for steroid-refractory acute GVHD (SR-aGVHD). Endothelial damage is a pathological substrate of aGVHD. Methods: Endothelial damage biomarkers were measured in SR-aGVHD patients' plasma before (PRE) and 1-month after initiating ECP as second-line therapy to explore differences by treatment response. ECP-treated SR-aGVHD patients (n=35) were classified into good (GR; n=18) and poor (PR; n=17) responders. Endothelial activation biomarkers (soluble Vascular Cell Adhesion Molecule-1, sVCAM-1; von Willebrand Factor, VWF; thrombomodulin, TM; soluble TNF receptor 1, sTNFR1; angiopoietin 2; ANG2); GVHD markers (suppression tumorigenicity 2, ST2; regenerating islet-derived 3-alpha, REG3alpha; T-cell immunoglobulinmucin-3, TIM3); soluble C5b9 (sC5b9), for complement activation; and circulating dsDNA, for neutrophil extracellular traps (NETs), were analyzed. The endothelial activation and stress index (EASIX) and C-reactive protein were evaluated. Results: Before ECP, endothelial damage biomarkers were elevated in all patients, with no significant differences between GR and PR. After 1-month, increased levels of REG3alpha and sC5b9, and decreased levels of TIM3, were observed in samples from PR. A panel combining 5 biomarkers (ST2, VWF, NETs, TIM3, ANG2) could identify GR after 1-month on ECP (likelihood ratio 2.0) and predict ECP response. Discussion: We propose a simplified endothelial damage biomarker panel capturing early biological signals associated with response to ECP in SR-aGVHD patients.

23 June 2026 in Blood Advances
Verified
Journal Article
Open access
BMBlanca De Moner
Blanca De Moner
JMJulia Martinez-Sanchez
Julia Martinez-Sanchez
SESilvia Escribano-Serrat
Silvia Escribano-Serrat
AMAna Belén Moreno-Castaño
Ana Belén Moreno-Castaño
PCPaola Andrea Charry
Paola Andrea Charry
MDMaribel Diaz-Ricart
Maribel Diaz-Ricart
Steroid-refractory acute GVHD (SR-aGVHD) is a severe complication of allogeneic hematopoietic cell transplantation. While endothelial dysfunction is implicated in aGVHD pathophysiology, the status of the endothelium in patients with SR-aGVHD and the effect of the JAK1/2 inhibitor ruxolitinib remain incompletely understood. This study aimed to characterize the endothelial damage phenotype induced by SR-aGVHD serum and to evaluate the potential modulatory effects of ruxolitinib. Human microvascular endothelial cells (HMEC-1) were exposed to serum from SR-aGVHD patients (n = 21) or healthy donors (C), with or without ruxolitinib (0.4 µM). Markers of endothelial activation (VCAM-1, ICAM-1), junctional integrity (VE-cadherin), prothrombotic state (VWF), apoptosis (cleaved caspase 3), and intracellular signalling (JAK-STAT and MAPK pathways) were analyzed by immunofluorescence and immunoblotting. Compared with C, SR-aGVHD serum caused increased VCAM-1 and ICAM-1 expression (P< .05 for both), reduced VE-cadherin (P< .01), elevated VWF production, and cleaved caspase 3 presence (P< .05 for both). These changes were associated with phosphorylation of STAT3 (P< .05), STAT1 (P< .05), and MAPK proteins (Erk1/2, p38, SAP/JNK, and cJun) (P< .05, all). Ruxolitinib treatment mitigated these responses, reducing adhesion molecule expression, restoring VE-cadherin localization, normalizing VWF production, and suppressing apoptosis. These protective effects were associated with inhibition of the activated JAK-STAT and MAPK signalling pathways. SR-aGVHD serum directly induces endothelial activation in vitro, promoting an inflammatory and prothrombotic phenotype. Ruxolitinib counteracts these effects, providing mechanistic insight into its therapeutic efficacy in SR-aGVHD.

19 April 2026 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
LCLaura Creus-Vilalta
Laura Creus-Vilalta
MSMaría Suárez-Lledó
María Suárez-Lledó
JMJulia Martinez-Sanchez
Julia Martinez-Sanchez
BMBlanca de Moner
Blanca de Moner
LRLAIA GUARDIA ROCA
LAIA GUARDIA ROCA
MSMaria Queralt Salas
Maria Queralt Salas
Hepatic sinusoidal obstruction syndrome (SOS) is a potentially life-threatening complication of allogeneic hematopoietic cell transplantation (allo-HCT) driven by endothelial injury. Post-transplant cyclophosphamide (PTCy) is widely used for graft-versus-host disease prophylaxis, but data on SOS incidence, risk factors, and outcomes in this setting are limited. The present study investigates the incidence and outcomes of SOS in adults undergoing allo-HCT with PTCy-based prophylaxis. This retrospective single-center study included 374 consecutive adult patients who underwent allo-HCT with PTCy between January 2014 and January 2025. SOS was diagnosed and graded according to established criteria. Endothelial activation was assessed using the Endothelial Activation and Stress Index (EASIX) at predefined peri-transplant time points. SOS occurred in 12 patients (3.2%), with a 100-day cumulative incidence of 2.7%. Six cases (50%) were moderate and six (50%) severe. Patients with myelofibrosis were markedly overrepresented (41.7% vs. 4.1%; P<0.001) and had an increased risk of SOS (HR 14.38, P<0.001). Median hospitalization was longer in SOS patients (46 vs. 29 days; P=0.01), and 16.6% required ICU admission. Ten patients (83.3%) received defibrotide and one underwent TIPS placement. Clinical response was observed in 91.7%, but seven patients (58.3%) died during follow-up, primarily from non-relapse mortality (NRM) (median 60 days). Two-year overall survival and NRM were 33.3% and 31.2% in SOS patients versus 71.8% and 12.6% in non-SOS patients. SOS was independently associated with higher NRM (HR 8.4, P<0.001) and inferior OS (HR 3.3, P=0.001). During the first 100 days, median EASIX values were higher in SOS patients. Higher log2-EASIX at pre-transplant evaluation (EASIX-PRE) and day 0 independently predicted SOS (HR 4.6; P=0.003). SOS remains an uncommon but clinically significant complication following allo-HCT with PTCy, substantially impacting survival. EASIX is a readily available biomarker that may enable early risk stratification and support individualized preventive strategies in this setting.